|
[1]
|
Agosti, V., Stewart, J.W. (1998). Social functioning and residual symptomatology among outpatients who responded to treatment and recovered from major depression. Journal of Affective Disorders, 47, 207-210. doi:10.1016/S0165-0327(97)00119-5
|
|
[2]
|
Amado-Boccara, I., Gougoulis, N., Poirier, L.M., Galinowski, A., & Loo, H. (1992). Effects of antidepressants on cognitive functions: A review. Neuroscience & Biobehavioral Reviews, 19, 479-493.doi:10.1016/0149-7634(94)00068-C
|
|
[3]
|
Audinot, V., Mailliet, F., Lahaye-Brasseur, C., Bonnaud, A., Le Gall, A., Amosse, C., Dromaint, S., Rodriguez, M., Nagel, N., Galizzi, J. P., Malpaux, B., Guillaumet, G., Lesieur, D., Lefoulon, F., Renard, P., Delagrange, P., & Boutin, J.A. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. NaunynSchmiedeberg’s Arch Pharmacol, 367, 553-561. doi:10.1007/s00210-003-0751-2
|
|
[4]
|
Austin, M., Mitchell, P., & Goodwin, G. ( 2001). Cognitive deficits in depression: Possible implications for functional neuropathology. Brit- ish Journal of Psychiatry, 178, 200-206. doi:10.1192/bjp.178.3.200
|
|
[5]
|
Blier, P., & Blondeau, C. (2011). Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depres- sive disorder. Journal of Affective Disorders, 128, S3-S10.doi:10.1016/S0165-0327(11)70003-9
|
|
[6]
|
Bondareff, W., Alpert, M., Friedhoff, A., Richter, E., Clary, C., & Batzar, E. (2000). Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. American Journal of Psychiatry, 157, 729-36. doi:10.1176/appi.ajp.157.5.729
|
|
[7]
|
Brodbeck, J., Abbott, R.A., Goodyer, I.M., & Croudace, T.J. (2011). General and specific components of depression and anxiety in an adolescent population. BMC Psychiatry, 11, 191.doi:10.1186/1471-244X-11-191
|
|
[8]
|
Cipriani, A., La Ferla, T., Furukawa, T.A., Signoretti, A., Nakagawa, A., Churchill, R., & Barbui, C. (2010). Sertraline versus other anti- depressive agents for depression. Cochrane Database of Systematic Reviews, 1.
|
|
[9]
|
Conradi, H. J., Ormel, J., & de Jonge, P. (2010). Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychological Medicine, 8, 1-10.
|
|
[10]
|
Corruble, E., Belaidi, C., & Goodwin, G. (2011). P02-24-Agomelatine versus escitalopram in major depressive disorders: A randomized double-blind, long term study focusing on sleep satisfaction and emotional blunting. European Psychiatry, 26, 619.
doi:10.1016/S0924-9338(11)72325-2
|
|
[11]
|
Cunningham, L., Borison, R., Carman, J., Chouinard, G., Crowder, J.E., Diamond, B.I., Fischer, D.E., & Hearst, E.(1994). A comparison of venlafaxine, trazodone, and placebo in major depression. Journal of Clinical Psychopharmacology, 15, 30-40.
|
|
[12]
|
Di Giannantonio, M., Di Iorio, G., Guglielmo, R., De Berardis, D., Conti, C.M., Acciavatti, T., Cornelio, M., & Martinotti, G. (2011). Major depressive disorder, anhedonia and agomelatine: An open-la- bel study. Journal of Biological Regulators & Homeostatic Agents, 25, 109-114
|
|
[13]
|
Demyttenaere, K. (2011). Agomelatine: A narrative review. European Neuropsychopharmacology, 21, S703-S709.
doi:10.1016/j.euroneuro.2011.07.004
|
|
[14]
|
Doraswaimy, P., Krishnan, K., Oxman, T., Jenkyn, L.R., Coffey, D.J., Burt, T., & Clary, C.M. (2003). Does antidepressant therapy improve cognition in elderly depressed patients? Journals of Gerontology, 12, 1137-1144.
|
|
[15]
|
Dunner, D.L., & Dunbar, G.C. (1992). Optimal dose for paroxetine. Journal of Clinical Psychiatry, 53, 21-26.
|
|
[16]
|
Farabaugh, A.H., Bitran, S., Witte, J., Alpert, J., Chuzi, S., Clain, A.J., & Papakostas, G. I. (2010). Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. International Clinical Psychopharmacology, 25, 214-217. doi:10.1097/YIC.0b013e328339fbbd
|
|
[17]
|
Fava, M., Rush, A.J., Alpert, J.E., Balasubramani, G.K., Wisniewski, S.R., Carmin, C.N., Biggs, M.M., Zisook, S., Leuchter, A., Howland, R., Warden, D., & Trivedi, M.H. (2008). Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. American Journal of Psychiatry, 165, 342-351.
doi:10.1176/appi.ajp.2007.06111868
|
|
[18]
|
Fekadu, A., Wooderson, S. C., Rane, L. J., Markopoulou, K., Poon, L., Cleare, A. J. (2011). Long-term impact of residual symptoms in treat- ment-resistant depression. Canadian Journal of Psychiatry, 56, 549-557.
|
|
[19]
|
Fossati, P., Amar, G., Raoux, N., Ergis, A., & Alligaire, J. (1999). Executive functioning and verbal memory in young patients with unipolar depression and schizophrenia. Psychiatry Research, 89, 171-187. doi:10.1016/S0165-1781(99)00110-9
|
|
[20]
|
Furlan, P., Kallan, M., Ten, T., Pollock, B. G., Katz, I., & Lucki, I. (2001). Cognitive and psychomotor effects of paroxetine and sertr- aline on healthy elderly volunteers. American Journal of Geriatric Psychiatry, 9, 429-437.
|
|
[21]
|
Gualtieri, C., & John, L. (2007). Bupropion normalizes cognitive per- formance in patients with depression. Medscape General Medicine, 9, 22.
|
|
[22]
|
Hale, A., Corral, R. M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, doubleblind study. International Clinical Psychopharmacology, 25, 305- 314. doi:10.1097/YIC.0b013e32833a86aa
|
|
[23]
|
Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.
doi:10.1111/j.2044-8341.1959.tb00467.x
|
|
[24]
|
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.
doi:10.1136/jnnp.23.1.56
|
|
[25]
|
Harmer, C.J., Shelley, N.C., Cowen, P.J., & Goodwin, G.M. (2004). Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepine- phrine reuptake inhibition. American Journal of Psychiatry, 7, 1256- 1263. doi:10.1176/appi.ajp.161.7.1256
|
|
[26]
|
Harmer, C.J., de Bodinat, C., Dawson, G.R., Dourish, C.T., Walden- maier, L., Adams, S., Cowen, P.J., & Goodwin, G.M. (2011). Ago- melatine facilitates positive versus negative affective processing in healthy volunteer models. Journal of Psychopharmacology, 25, 1159-1167. doi:10.1177/0269881110376689
|
|
[27]
|
Joyce, P.R., Mulder, R.T., McKenzie, J.M., Luty, S.E., & Cloninger, C.R. (2004). Atypical depression, atypical temperament and a dif- ferential antidepressant response to fluoxetine and nortriptyline. De- pression and Anxiety, 19, 180-186. doi:10.1002/da.20001
|
|
[28]
|
Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W.J., Montejo, A.L., Smeraldi, E., Rybakowski, J.K., Quera-Salva, M.A., Wirz-Justice, A.M., Picarel-Blanchot, F., & Baylé, F.J. (2010). Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. Journal of Clinical Psychiatry, 71, 109-120.
doi:10.4088/JCP.09m05347blu
|
|
[29]
|
Keller, M. B., Lavori, P. W., Friedman, B., Nielsen, E., Endicott, J. et al. (1987). The longitudinal follow-up evaluation: A comprehensive method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry, 44, 540-548.
doi:10.1001/archpsyc.1987.01800180050009
|
|
[30]
|
Keltner, N. L., McAfee, K. M., & Taylor, C. L. (2002). Mechanisms and treatments of SSRI induced sexual dysfunction. Perspectives in Psy- chiatric Care, 38, 111-116. doi:10.1111/j.1744-6163.2002.tb00665.x
|
|
[31]
|
Kendell, R. E. (1975). The role of diagnosis in psychiatry. Oxford: Blackwell Scientific Publications.
|
|
[32]
|
Kennedy, S. H., & Emsley, R. (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neu- ropsychopharmacology, 16, 93-100.
doi:10.1016/j.euroneuro.2005.09.002
|
|
[33]
|
Kennedy, S.H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology, 28, 329-333.
doi:10.1097/JCP.0b013e318172b48c
|
|
[34]
|
Kennedy, S.H., & Rizvi, S.J. (2009). Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs, 14, 439-453.doi:10.1517/14728210903107751
|
|
[35]
|
Kennedy, S.H, & Rizvi, S.J. (2010). Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs, 24, 479-499. doi:10.2165/11534420-000000000-00000
|
|
[36]
|
Korszun, A., Moskvina, V., Brewster, S., Craddock, N., Ferrero, F., Gill, M., Jones, I.R., Jones, L.A., Maier, W., Mors, O., Owen, M.J., Preisig, M., Reich, T., Rietschel, M., Farmer, A., & McGuffin, P. (2004). Familiality of symptom dimensions in depression. Archives of General Psychiatry, 61, 468-474. doi:10.1001/archpsyc.61.5.468
|
|
[37]
|
Laux, G. (2011). P02-52—The antidepressant efficacy of agomelatine in daily practice: Results of the non-interventional study VIVALDI. European Psychiatry, 26, 647. doi:10.1016/S0924-9338(11)72353-7
|
|
[38]
|
Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723-1732.doi:10.4088/JCP.v68n1112
|
|
[39]
|
Liemburg, E., Aleman, A., Bous, J., Hollander, K., & Knegtering, H. (2011). An open randomized pilot trial on the differential effects of aripiprazoleversus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry, 44, 109-113. doi:10.1055/s-0031-1271688
|
|
[40]
|
L?o, H., Hale, A., & D’haenen, H. (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) anta- gonist, in the treatment of major depressive disorder: A placebo- controlled dose range study. International Clinical Psychopharmacology, 17, 239-247. doi:10.1097/00004850-200209000-00004
|
|
[41]
|
McCabe, C., Mishor, Z., Cowen, P.J., & Harmer, C.J. (2010). Dimi- nished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biological Psychiatry, 67, 439-445. doi:10.1016/j.biopsych.2009.11.001
|
|
[42]
|
McKnight, P.E., & Kashdan, T.B. (2009). The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research. Clinical Psychology Review, 29, 243-259. doi:10.1016/j.cpr.2009.01.005
|
|
[43]
|
McMakin, D.L, Olino, T.M., Porta, G., Dietz, L.J., Emslie, G., Clarke, G., Wagner, K.D., Asarnow, J.R, Ryan, N.D., Birmaher, B., Sham- seddeen, W., Mayes, T., Kennard, B., Spirito, A., Keller, M., Lynch, F.L., Dickerson, J.F., & Brent, D.A. (2012). Anhedonia predicts poorer recovery among youth with selective serotonin reuptake in- hibitor treatment resistant-depression. Journal of the American Academy of Child and Adolescent Psychiatry, 51, 404-411.
doi:10.1016/j.jaac.2012.01.011
|
|
[44]
|
Mendels, J., Johnston, R., Mattes, J., & Riesenberg, R. (1993). Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
|
|
[45]
|
Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M., & Cussac, D. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxy-tryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics, 306, 954-964.doi:10.1124/jpet.103.051797
|
|
[46]
|
Montejo, A., Majadas, S., Rizvi, S., & Kennedy, S.H. (2011). The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology-Clinical and Experimental, 26, 537-542. doi:10.1002/hup.1243
|
|
[47]
|
Montgomery, S.A., & Asberg, A. (1979). A new depression scale designed to be sensitive to change. The British Journal of Psychiatry, 134, 382-389. doi:10.1192/bjp.134.4.382
|
|
[48]
|
Montgomery, S.A., & Kasper, S. (2007). Severe depression and anti- depressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology, 22, 283-291. doi:10.1097/YIC.0b013e3280c56b13
|
|
[49]
|
Olie, J.P., & Kasper, S. (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major de- pressive disorder. International Journal of Neuropsychopharmacol- ogy, 10, 661-673.
|
|
[50]
|
Opbroek, A., Delgado, P.L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F.A., & Manber, R. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5, 147-151. doi:10.1017/S1461145702002870
|
|
[51]
|
Ossewaarde, L., Verkes, R.J., Hermans, E.J., Kooijman, S.C., Urner,M., Tendolkar, I., van Wingen, G.A., & Fernandez, G. (2011). Two-week administration of the combined serotonic-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biological Psychiatry, 70, 568-574.
doi:10.1016/j.biopsych.2011.03.041
|
|
[52]
|
Nierenberg, A.A., & Wright, E.C. (1999). Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry, 60, 7-11.
|
|
[53]
|
Novotny, V., & Pecenák, J. (2011). Agomelatine—First results from trial VALID in Slovakia. International Journal of Psychiatry in Clinical Practice, 33-34.
|
|
[54]
|
Papakostas, G.I., & Larsen, K. (2011). Testing anxious depression as a predictor and moderator of symptom improvement in major depresssive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience, 261, 147-156. doi:10.1007/s00406-010-0149-3
|
|
[55]
|
Parker, G., Wilhelm, K., Mitchell, P., Roy, K., & Hadzi-Pavlovic, D. (1999). Subytping depression: Testing algorithms and identification of a tiered model. Journal of Nervous and Mental Disease, 187, 610- 617. doi:10.1097/00005053-199910000-00004
|
|
[56]
|
Perry, P.J. (1996). Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders, 39, 1-6. doi:10.1016/0165-0327(96)00014-6
|
|
[57]
|
Porter, R., Gallagher, P., Thompson, J., & Young, A. (2003). Neuro-cognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry, 182, 214-220. doi:10.1192/bjp.182.3.214
|
|
[58]
|
Quera-Salva, M.A., Hajak, G., Philip, P., Montplaisir, J., Keufer-Le Gall, S., Laredo, J., & Guilleminault, C. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology, 26, 252-262.doi:10.1097/YIC.0b013e328349b117
|
|
[59]
|
Racagni, G., Riva, M.A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011). Mode of action of agomelatine: Synergy between melatonergic and 5-HT2c receptors. The World Journal of Biological Psychiatry, 12, 574-587.
doi:10.3109/15622975.2011.595823
|
|
[60]
|
Raskin, J., Wiltse, C.G., Siegal, A., Javaid, S., Xu, J., Dinkel, J.J., Rotz, B.T., & Mohs, R.C. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. American Journal of Psychiatry, 164, 900-909. doi:10.1176/appi.ajp.164.6.900
|
|
[61]
|
Sheehan, D.V., Harnett-Sheehan, K., & Raj, B.A. (1996). The measurement of disability. International Clinical Psychopharmacology, 11, 89-95. doi:10.1097/00004850-199606003-00015
|
|
[62]
|
Silverstone, P.H., Entsuah, R., & Hackett, D. (2002). Two items on the Hamilton Depression rating scale are effective predictors of remis- sion: Comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. International Clinical Psychopharmacology, 17, 273-280.
doi:10.1097/00004850-200211000-00002
|
|
[63]
|
Snaith, R.P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P.(1995). A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. British Journal of Psychiatry, 67, 99-103. doi:10.1192/bjp.167.1.99
|
|
[64]
|
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Mendlewicz, J. (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. Journal of Clinical Psychiatry, 68, 1062-1070.
doi:10.4088/JCP.v68n0713
|
|
[65]
|
Stahl, S.M., Fava, M., Trivedi, M.H., Caputo, A., Shah, A., & Post, A. (2010). Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 71, 616-626.
doi:10.4088/JCP.09m05471blu
|
|
[66]
|
Stein, D.J., Ahokas, A.A., & de Bodinat, C. (2008). Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 561-566. doi:10.1097/JCP.0b013e318184ff5b
|
|
[67]
|
Stein, D.J., & Kennedy, S.H. (2011). Efficacy of the novel antide- pressant agomelatine for anxiety symptoms within depression. Euro- pean College of Neuropsychopharmacology Annual Meeting, Paris, 5 September 2011.
|
|
[68]
|
Uher, R., Farmer, A., Maier, W., Rietschel, M., Hauser, J., Marusic, A., Mors, O., Elkin, A., Williamson, R.J., Schmael, C., Henigsberg, N., Perez, J., Mendlewicz, J., Janzing, J.G., Zobel, A., Skibinska, M., Kozel, D., Stamp, A.S., Bajs, M., Placentino, A., Barreto, M., Mc-Guffin, P., & Aitchison, K.J. (2008). Measuring depression: Com- parison and integration of three scales in the GENDEP study. Psychological Medicine, 38, 289-300. doi:10.1017/S0033291707001730
|
|
[69]
|
Uher, R., Maier, W., Hauser, J., Marusic, A., Schmael, C., Mors, O., Henigsberg, N., Souery, D., Placentino, A., Rietschel, M., Zobel, A., Dmitrzak-Weglarz, M., Petrovic, A., Jorgensen, L., Kalember, P., Giovannini, C., Barreto, M., Elkin, A., Landau, S., Farmer, A., Aitchison, K.J., & McGuffin, P. (2009). Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 194, 252-259. doi:10.1192/bjp.bp.108.057554
|
|
[70]
|
Wade, A.G., Fernández, J.L., Fran?ois, C., Hansen, K., Danchenko, N., & Despiegel, N. (2008). Escitalopram and duloxetine in major depressive disorder: A pharmacoeconomic comparison using UK cost data. Pharmacoeconomics, 26, 969-981.
doi:10.2165/00019053-200826110-00008
|
|
[71]
|
Waldinger, M.D., Zwinderman, A.H., & Olivier, B. (2003). Antide-pressants and ejaculation: A double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. Journal of Clinical Psychopharmacology, 23, 467-470.
doi:10.1097/01.jcp.0000088904.24613.e4
|
|
[72]
|
Warden, D., Trivedi, M. H., Wisniewski, S. R., Davis, L., Nierenberg, A. A., Gaynes, B. N., & Rush, A. J. (2007). Predictors of attrition during initial (citalopram) treatment for depression: A STAR*D report. American Journal of Psychiatry, 164, 1189-1197. doi:10.1176/appi.ajp.2007.06071225
|
|
[73]
|
Zajecka, J., Schatzberg, A., Stahl, S., Shah, A., Caputo, A., & Post, A. (2010). Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 30, 135-144. doi:10.1097/JCP.0b013e3181d420a7
|
|
[74]
|
Zigmond, A.S., & Snaith, R.P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361-370.
doi:10.1111/j.1600-0447.1983.tb09716.x
|
|
[75]
|
Zimmerman, M., Ruggero, C.J., Chelminski, I., Young, D., Posternak, M.A., Friedman, M., Boerescu, D., & Attiullah, N. (2006). Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. Journal of Clinical Psychiatry, 67, 1536-1541.doi:10.4088/JCP.v67n1007
|